Abstract

The recently published College mood disorders clinical practice guidelines (Malhi et al., 2021) are dazzling in their breadth, comprehensiveness and erudition. They intelligently criticise the concepts of depression and bipolar illnesses. (Rosenman, 2021)
Akin to a William Morris tapestry, Dr Stephen Rosenman explicates the ACE (activity, cognition and emotion) Model described in the recent mood disorder clinical practice guidelines (CPGs) and extrudes the analogy through his mental loom, so as to create a marvellous image of the material of mood disorders.
We concur entirely with the view that ‘careful discriminations of phenomena ground practice in psychiatry’ and that ‘there is no obvious limit to the fineness of those discriminations’ and furthermore, that ‘good practice means making relevant discriminations up to the limits of our time, our language and our experience’.
We also share his critical view of the current approach to taxonomy that entails the generation of categorical diagnoses, many of which lack validity (e.g. disruptive mood dysregulation disorder [DMDD], Bipolar II disorder) (Malhi and Bell, 2019a, 2019b). To this end, his suggestion of supplanting the concept of bipolar disorder with the ACE model is intriguing and perhaps this is precisely the kind of avant-garde thinking that is needed. Interestingly, the shift away from the traditional subtyping of bipolar disorder to a more dimensional approach that better accommodates mixed presentations has been widely welcomed.
Similarly, the introduction of new paradigms such as channelling response has been greeted with enthusiasm. These are important ‘inventions’ as they provide new perspectives on clinical challenges and practice. But as Rosenman states, they remain ‘imaginative hypotheses’ and as such, they require vigorous interrogation and robust testing. For example, our Windows of Antidepressant Response Paradigm (WARP) may be useful in devising future clinical trials, especially where agents purported to have rapid actions are investigated. This would also test the utility of the paradigm and allow it to be further refined, if found to be useful. Similarly, our Channelling Response Paradigm (CRP) can perhaps provide a framework for naturalistic treatment studies conducted in real-world populations, in a similar vein to landmark studies such as STAR*D (Rush et al., 2004).
Dr Rosenman’s description of the guidelines as ‘intellectually dazzling’ is balanced by his well-founded concern that psychiatric diagnoses of disorders and paradigms for psychiatric management need to constantly evolve and strive harder to better capture reality. While we share his, and arguably mainstream psychiatry’s, belief that the current binary diagnoses do not adequately capture the descriptive landscape of mental health (which has prominent dimensional components like A, C and E), we have had to be pragmatic and construct a guideline on the available evidence which derives principally from a taxonomy based on binary diagnoses.
We thus extend an invitation to everyone to assist us in further bedazzling future iterations of the guidelines and help us escape the confines of our thinking.
Footnotes
Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: G.S.M. has received grant or research support from National Health and Medical Research Council, Australian Rotary Health, NSW Health, American Foundation for Suicide Prevention, Ramsay Research and Teaching Fund, Elsevier, AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka and Servier; and has been a consultant for AstraZeneca, Janssen-Cilag, Lundbeck, Otsuka and Servier. D.B. has received funding to host webinars by Lundbeck. P.B. has received research support from the National Health and Medical Research Council; speaker fees from Servier, Janssen and the Australian Medical Forum; and educational support from Servier and Lundbeck; has been a consultant for Servier; served on an advisory board for Lundbeck; and has served as DSMC Chair for Douglas Pharmaceuticals. R.M. has received support for travel to education meetings from Servier and Lundbeck, speaker fees from Servier and Committee fees from Janssen. G.M. has received grant support in the last 5 years from the National Health and Medical Research Council, the Mental Illness Research Fund, Victorian Medical Research Acceleration Fund, Canadian Institutes of Health Research, Readiness, SiSU Wellness and Barbara Dicker Foundation. M.H. has received grant or research support in the last 5 years from the National Health and Medical Research Council, Medical Research Future Fund, Ramsay Health Research Foundation, Boehringer-Ingleheim, Douglas, Janssen-Cilag, Lundbeck, Lyndra, Otsuka, Praxis and Servier; and has been a consultant for Janssen-Cilag, Lundbeck, Otsuka and Servier. A.S. has shares/options in Baycrest Biotechnology Pty Ltd (pharmacogenetics company) and Greenfield Medicinal Cannabis, and has received speaking honoraria from Servier, Lundbeck and Otsuka Australia. R.P. has received support for travel to educational meetings from Servier and Lundbeck and uses software for research at no cost from Scientific Brain Training Pro. The author E.B. declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Funding
The author(s) received no financial support for the research, authorship and/or publication of this article.
